These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 9408313

  • 1. The role of different tumor markers in the early diagnosis and prognosis of pancreatic carcinoma and chronic pancreatitis.
    Hámori J, Arkosy P, Lenkey A, Sápy P.
    Acta Chir Hung; 1997; 36(1-4):125-7. PubMed ID: 9408313
    [Abstract] [Full Text] [Related]

  • 2. [Accuracy of imaging techniques and tumor markers in the diagnosis of pancreatic cancer].
    Clavé P, Boadas J, González-Carro P, Mora J, Pérez C, Martínez A, Roca M, Lluís F, Farré A.
    Gastroenterol Hepatol; 1999; 22(7):335-41. PubMed ID: 10535205
    [Abstract] [Full Text] [Related]

  • 3. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
    Jiang XT, Tao HQ, Zou SC.
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
    [Abstract] [Full Text] [Related]

  • 4. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
    Kokhanenko NIu, Ignashov AM, Varga EV, Polkanova MS, Aleshina LA, Kimbarovskaia AA, Osipenko SK, Lebedev EG.
    Vopr Onkol; 2001 Aug; 47(3):294-7. PubMed ID: 11544826
    [Abstract] [Full Text] [Related]

  • 5. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
    Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S.
    Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
    [Abstract] [Full Text] [Related]

  • 6. Clinical value of serum TAG-72 as a tumor marker for pancreatic carcinoma. Comparison with CA 19-9.
    Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S.
    Int J Pancreatol; 1994 Jun; 15(3):171-7. PubMed ID: 7930777
    [Abstract] [Full Text] [Related]

  • 7. [Ca 19-9 antigen in differentiation of pancreatic inflammatory and neoplastic tumors].
    Markocka-Maczka K.
    Wiad Lek; 2003 Jun; 56(11-12):537-40. PubMed ID: 15058160
    [Abstract] [Full Text] [Related]

  • 8. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 9. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
    Ozkan H, Kaya M, Cengiz A.
    Hepatogastroenterology; 2003 Mar; 50(53):1669-74. PubMed ID: 14571813
    [Abstract] [Full Text] [Related]

  • 10. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
    Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E.
    Hepatogastroenterology; 2000 Mar; 47(36):1750-2. PubMed ID: 11149048
    [Abstract] [Full Text] [Related]

  • 11. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
    Pezzilli R, Billi P, Plate L, Laudadio MA, Sprovieri G.
    Ital J Gastroenterol; 1995 Mar; 27(6):296-9. PubMed ID: 8562994
    [Abstract] [Full Text] [Related]

  • 12. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ, de Bruijn HW, Hollema H, ten Hoor KA, Willemse PH, Aalders JG, van der Zee AG.
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [Abstract] [Full Text] [Related]

  • 13. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
    Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM.
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
    Satake K, Kanazawa G, Kho I, Chung Y, Umeyama K.
    Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
    [Abstract] [Full Text] [Related]

  • 15. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K.
    J Hepatobiliary Pancreat Surg; 2007 Aug; 14(6):539-44. PubMed ID: 18040617
    [Abstract] [Full Text] [Related]

  • 16. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.
    Chang MC, Chang YT, Su TC, Yang WS, Chen CL, Tien YW, Liang PC, Wei SC, Wong JM.
    Pancreas; 2007 Jul; 35(1):16-21. PubMed ID: 17575540
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
    Wu X, Lu XH, Xu T, Qian JM, Zhao P, Guo XZ, Yang XO, Jiang WJ.
    Chin J Dig Dis; 2006 Jul; 7(3):170-4. PubMed ID: 16808798
    [Abstract] [Full Text] [Related]

  • 18. Significance of serum tumor markers carcinoembryonic antigen, CA 19-9, CA 125, and CA 15-3 in pre-orthotopic liver transplantation evaluation.
    Pissaia A, Bernard D, Scatton O, Soubrane O, Conti F, Calmus Y.
    Transplant Proc; 2009 Mar; 41(2):682-4. PubMed ID: 19328956
    [Abstract] [Full Text] [Related]

  • 19. Atypical courses of serum tumor markers--4 case reports.
    Klapdor R, Bahlo M, Babinski A.
    Anticancer Res; 2003 Mar; 23(2A):845-50. PubMed ID: 12820311
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.